Skip to main content
Fig. 11 | BMC Biotechnology

Fig. 11

From: High-level expression of a novel liver-targeting fusion interferon with preferred Escherichia coli codon preference and its anti-hepatitis B virus activity in vivo

Fig. 11

Effect of IFN α2b, IFN-CSP on serum HBsAg (a) and HBV-DNA (b) level in HBV-transgenic mice. (a) physiological saline control; (b) IFN α2b, 103 U/g body weight; (c) IFN-CSP, 101 U/g body weight; (d) IFN-CSP, 102 U/g body weight; (e) IFN-CSP, 103 U/g body weight. The treatment continued for 28 days, serum HBsAg levels were measured by ELISA assay. The results are represented as OD value of sample/OD value of negative control. Serum HBV-DNA levels were measured by fluorescent quantification polymerase chain reaction (PCR). The copies of the HBV-DNA were calculated based on their Ct value and the standard curves. The data are the mean ± SEM from six mice. *P < 0.05 vs physiological saline controls, **P < 0.01 vs physiological saline controls, # # P < 0.01 vs IFN α2b controls

Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us